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respectively; in the placebo group, PCr fell by 0.7 %. There 
was no group difference in adverse events, weight gain or 
serum creatinine. Regression analysis of PCr and depres-
sion scores across the entire sample showed that frontal 
lobe PCr was inversely correlated with depression scores 
(p = 0.02). These results suggest that CM achieves target 
engagement with brain bioenergetics and that the target is 
correlated with a clinical signal. Further study of CM as a 
treatment for adolescent females with SSRI-resistant MDD 
is warranted.
Keywords Creatine monohydrate · Phosphocreatine · 
Bioenergetics · Mitochondrial function · Adolescent 
depression · Women’s health · Phosphorus-31 magnetic 
resonance spectroscopy
Introduction
Depressive disorders are the second leading cause of years 
lived with disability as of 2010 (Ferrari et al. 2013) and 
major depressive disorder (MDD) is projected to become 
the leading cause of global disease burden by 2030 (Lepine 
and Briley 2011). The onset of MDD commonly occurs 
during adolescence (Burke et al. 1991); in fact, MDD has 
a cumulative prevalence of 15–24 % by age 19 (Lewin-
sohn et al. 1998; Merikangas et al. 2010) and results in 
significant disability and mortality in this age group (Bir-
maher et al. 2007). Selective serotonin reuptake inhibitors 
(SSRIs) are first-line medications for adolescents requir-
ing MDD pharmacotherapy (Lewandowski et al. 2013); 
however, ~40 % of depressed adolescents fail to respond 
to initial treatment with an SSRI (Brent et al. 2008). These 
adolescents with treatment-resistant depression (TRD) are 
at risk for recurrence into adulthood, academic and social 
Abstract Major depressive disorder (MDD) often 
begins during adolescence and is projected to become the 
leading cause of global disease burden by the year 2030. 
Yet, approximately 40 % of depressed adolescents fail to 
respond to standard antidepressant treatment with a selec-
tive serotonin reuptake inhibitor (SSRI). Converging evi-
dence suggests that depression is related to brain mitochon-
drial dysfunction. Our previous studies of MDD in adult 
and adolescent females suggest that augmentation of SSRI 
pharmacotherapy with creatine monohydrate (CM) may 
improve MDD outcomes. Neuroimaging with phospho-
rus-31 magnetic resonance spectroscopy (31P-MRS) can 
measure the high-energy phosphorus metabolites in vivo 
that reflect mitochondrial function. These include phos-
phocreatine (PCr), a substrate for the creatine kinase reac-
tion that produces adenosine triphosphate. As part of the 
National Institute of Mental Health’s experimental medi-
cine initiative, we conducted a placebo-controlled dose-
ranging study of adjunctive CM for adolescent females 
with SSRI-resistant MDD. Participants were randomized 
to receive placebo or CM 2, 4 or 10 g daily for 8 weeks. 
Pre- and post-treatment 31P-MRS scans were used to meas-
ure frontal lobe PCr, to assess CM’s target engagement 
with cerebral energy metabolism. Mean frontal lobe PCr 
increased by 4.6, 4.1 and 9.1 % in the 2, 4 and 10 g groups, 
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impairment and suicide (Zhou et al. 2014). The Treat-
ment of SSRI-Resistant Depression in Adolescents (TOR-
DIA) trial found that ~60 % of adolescents with TRD did 
not respond, when switched to a different SSRI or another 
antidepressant class (Brent et al. 2008). An alternative to 
switching medications is to introduce an adjunctive treat-
ment, a strategy that has shown promise in the management 
of adults with TRD (Rush et al. 2009). Despite the public 
health importance of improving care for adolescent MDD, 
controlled clinical trials of augmentation strategies for ado-
lescents with TRD are lacking.
During puberty (Angold et al. 1998), the prevalence of 
MDD among females rises to approximately twice that 
found in males (prevalence ratio 1.3–3.1; lifetime gender 
ratio 2.1) (Kuehner 2003), a finding that is robust to epide-
miologic sampling across continents and cultures (Seedat 
et al. 2009). Thus, female adolescents are affected by MDD 
at twice the rate of males (Merikangas et al. 2010), a gen-
der disparity that continues throughout the reproductive 
years (Bebbington et al. 2003; Robins and Regier 1991). 
Yet despite the evidence for gender-based differences 
in MDD pathophysiology (Hyde et al. 2008; Young and 
Korszun 2010) and treatment response (Yang et al. 2011; 
Bigos et al. 2009), little systematic research has focused on 
these empirical differences. In addition to the doubling of 
depression prevalence by the middle teenage years (Wade 
et al. 2002), girls with MDD have longer episodes and 
higher symptom severity compared to boys (McCauley 
et al. 1993) and a prolonged risk of recurrence compared 
with women whose first depressive episode occurs in adult-
hood (Kovacs 1996). Therefore, investigation of females 
with MDD during the critical ‘window of vulnerability’ 
that occurs in adolescence (Andersen and Teicher 2008; 
Hankin et al. 1998) provides a unique opportunity to reduce 
the burden of illness associated with depression.
Converging lines of evidence suggest that mitochondrial 
dysfunction and altered brain bioenergetics may contrib-
ute to the etiology of depression (Klinedinst and Regenold 
2015; Gardner and Boles 2011). The neuroimaging tech-
nique phosphorus-31 magnetic resonance spectroscopy 
(31P-MRS) is the sole method for noninvasive, in vivo 
measurement of the high-energy phosphorus metabolites 
that reflect cerebral bioenergetics (Agarwal et al. 2010; 
Kondo et al. 2011a; Zhu et al. 2009). These include phos-
phocreatine (PCr), beta-nucleoside triphosphate (β-NTP; 
largely adenosine triphosphate, ATP) and inorganic phos-
phate (Pi) (Iosifescu et al. 2008). PCr is the substrate res-
ervoir for the creatine kinase reaction (Wallimann et al. 
1992; Jeong et al. 2011). In mitochondria, this reaction 
reversibly converts PCr into ATP + creatine in a 1:1 molar 
ratio (Brosnan and Brosnan 2007; Wallimann et al. 2011). 
Neuronal energy demands are met through a shift in reac-
tion equilibrium, which is designed to maintain brain ATP 
concentrations constant (Andres et al. 2008; Schlattner 
et al. 2006).
Our previous translational studies of MDD reveal a pat-
tern in baseline/pre-treatment 31P-MRS metabolites, in 
subjects who later respond to treatment in a clinical trial 
setting: increased PCr (Iosifescu et al. 2008) and decreased 
β-NTP (Renshaw et al. 2001). The pattern is more common 
in females (Renshaw et al. 2001); this fact, when combined 
with the evidence for gender dimorphism in frontal lobe 
PCr and Pi in healthy females (Riehemann et al. 1999), 
suggested that it might be possible to target bioenergetic 
metabolism in the development of novel treatments for 
females with MDD. To investigate this, we first sought to 
determine whether the concentration of 31P-MRS metabo-
lites in brain could be modified by administration of cre-
atine monohydrate (CM). In a placebo-controlled study of 
healthy adults, we found that cerebral PCr and Pi increased 
and β-NTP decreased, in subjects receiving oral CM versus 
placebo (Lyoo et al. 2003). This reproduced the alterations 
in 31P-MRS metabolites that predict responsiveness, in 
two distinct groups of MDD patients: (1) treatment-naïve 
subjects receiving initial pharmacotherapy with an SSRI 
(Renshaw et al. 2001); and (2) SSRI-resistant subjects who 
receive hormonal augmentation of their existing antidepres-
sant (Iosifescu et al. 2008). These results raised the possi-
bility that CM supplementation could be utilized to promote 
a ‘treatment-responsive state’ in both MDD and TRD. As 
an initial step, we recruited unmedicated female adults with 
MDD for a placebo-controlled trial of CM versus placebo, 
each added to the SSRI escitalopram. Compared with the 
SSRI + placebo group, subjects who received SSRI + cre-
atine showed greater improvements in depression scores as 
early as week 2 of treatment (Lyoo et al. 2012), suggesting 
that adjunctive CM speeds response and increases remis-
sion in women with MDD. An open-label study of TRD in 
either MDD or BD also found that CM showed evidence 
of benefit in unipolar depression (Roitman et al. 2007). In 
parallel with our study of adult females, we also conducted 
a small-scale (n = 5) open-label study of CM in adoles-
cent females with TRD who had failed to respond to a trial 
of the SSRI fluoxetine. 31P-MRS scans of the frontal lobe 
were acquired at baseline and repeated after 8 weeks of CM 
4 g daily, with healthy control (HC) adolescent females 
scanned for comparison. The study’s results included a 
mean 56 % reduction in CDRS-R depression scores and an 
increase in PCr (p = 0.02) in female adolescents with TRD 
compared to HC (Kondo et al. 2011b).
In an effort to accelerate treatment development in 
psychiatry, the U.S. National Institute of Mental Health 
(NIMH) recently announced the NIMH Experimental 
Medicine Initiative (Insel 2015). The initiative requires 
that NIMH-funded clinical trials shift their emphasis from 
tests of clinical efficacy, e.g., reduction in depression 
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scores, to studies of disease mechanism (Insel and Gogtay 
2014). This requires a translational demonstration of target 
engagement, where the ‘target’ is a molecular site or brain 
circuit linked to a mechanism of disease, the mechanism of 
action of the treatment under study, or both. The new trial 
format is designed to yield insight into how or for whom 
the targeted intervention works and potentially measures 
duration and dose–response. The data from clinical trials 
are then informative, regardless of a study’s results: if the 
intervention engages the target and correlates with a signal 
in the clinical data, then development of the treatment—and 
those aimed at the same target—continues. If not, then the 
target’s mechanistic relevance is ruled out, and the focus 
shifts to identifying new treatment targets. Based upon the 
preliminary studies described above, we received one in 
the initial wave of NIMH phased innovation awards (R21/
R33). This report presents the findings from the R21 proof-
of-principle study, a dose-ranging trial of CM for adoles-
cent females with SSRI-resistant depression. The CM 
dose administered in our open-label study was 4 g daily, 
which was safe and well tolerated (Kondo et al. 2011b). 
We therefore tested one lower dose (2 g) and one higher 
dose (10 g) in this study, in addition to placebo. The speci-
fied target of CM treatment was frontal lobe PCr, because 
of its association with treatment response in prior stud-
ies of MDD and TRD. In fact, pre-treatment PCr predicts 
subsequent treatment ‘responder’ versus ‘non-responder’ 
status in TRD with an accuracy of 79 % (83 % sensitiv-
ity; 75 % specificity) (Iosifescu et al. 2008). Because our 
open-label adolescent data were collected in females, there 
were no extant placebo-controlled CM data in males with 
TRD and, perhaps, most importantly, because preclinical 
animal data suggest CM has antidepressant-like effects in 
female rats but is equivocal in males (Allen et al. 2010, 
2015), the study’s enrollment was limited to adolescent 
females. In addition, more recent data suggest CM’s anti-
depressant-like effects are sex hormone dependent (Allen 
et al. 2015). The aims of this R21 were: to demonstrate that 
CM targets and alters brain energy metabolism in female 
adolescents with SSRI-resistant MDD in a dose-responsive 
manner, compared with placebo; and to determine the dose 
of CM offering the best combination of safety, tolerability 
and target engagement with mitochondrial function in these 
participants.
Methods
This was a single-site, placebo-controlled, dose-finding 
clinical trial of CM augmentation for adolescent females 
with SSRI-resistant MDD (ClinicalTrials.gov registry num-
ber: NCT01601210). The study was conducted under U.S. 
Food and Drug Administration Investigational New Drug 
(IND) application #104586 issued to Dr. Renshaw, and 
the University of Utah Institutional Review Board (IRB) 
approved this research. Written and verbal informed con-
sent was obtained prior to performance of any research-
related procedures: (1) parental permission and participant 
assent, for participants aged <18 years; or (2) participant 
consent, for participants ≥ age 18 years. An external Data 
Safety and Monitoring Board with authority to halt the 
study monitored the study’s safety outcomes and risks to 
participants.
Participants
Participants were recruited through clinician referrals and 
IRB-approved advertising. The inclusion criteria were: 
females aged 13–20 years with a primary diagnosis of MDD; 
outpatient status; SSRI treatment for ≥8 weeks at a dosage of 
≥40 mg/day fluoxetine or its equivalent; current Children’s 
Depression Rating Scale-Revised (CDRS-R) (Poznanski and 
Mokros 1996; Mayes et al. 2010) raw score of >40 or Mont-
gomery–Asberg Depression Rating Scale (MADRS) (Mont-
gomery and Asberg 1979) score >25; and current Clinical 
Global Impression Scale-Severity (CGI-S) (Guy 1976) score 
≥4, indicating moderate severity of the current depressive 
episode. Diagnoses were established through administration 
of the Kiddie Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children-Present and Lifetime Ver-
sion (K-SADS-PL) (Kaufman et al. 1997), or the Structured 
Clinical Interview for DSM-IV Axis I Disorders (SCID-CT) 
(First et al. 2007). All psychopharmacological treatments 
were stable for ≥30 days at study entry, and participants 
were asked to hold their psychotropic medication regimens 
constant during the 8 weeks of randomized treatment. The 
study exclusion criteria were: pre-existing renal disease or 
proteinuria on baseline urinalysis testing; history of CM 
hypersensitivity or a previous failed therapeutic trial of CM; 
concomitant treatment with antiepileptic or antipsychotic 
medications; current substance use disorder; unstable comor-
bid medical, neurological or psychiatric disorder; clinically 
significant suicidal or homicidal risk; positive pregnancy 
test or refusal to practice contraception or abstinence during 
the study; current breastfeeding; positive urine drug screen; 
known or suspected intellectual disability; and any contrain-
dication to 31P-MRS imaging, e.g. ferromagnetic implant or 
claustrophobic anxiety. A complete blood count, compre-
hensive metabolic panel, urinalysis, urine drug screen and 
12-lead electrocardiogram (ECG) were obtained at baseline, 
and testing was repeated at the conclusion of randomized 
treatment, to prospectively identify abnormalities associated 
with CM administration. Participants attended weekly clinic 
visits for the first 4 weeks and then bi-weekly visits through 
week 8 of treatment. At each visit, the CDRS-R and CGI-S 
were administered.
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Phosphorus‑31 magnetic resonance spectroscopy 
(31P‑MRS) neuroimaging
Neuroimaging was performed on a Siemens 3 T whole-
body clinical scanner (Siemens Medical Solutions, Erlan-
gen, Germany) that is FDA approved for clinical use. Par-
ticipants first underwent a routine MRI protocol to acquire 
anatomic images in the axial and coronal planes. The pro-
tocol consists of a T1-weighted structural scan (MPRAGE), 
a double-echo T2-weighted scan and a fluid attenuated 
inversion recovery (FLAIR) scan. Examinations were per-
formed with a quadrature radiofrequency coil (Clinical 
MR Solutions LLC, Brookfield, WI, USA). After localiza-
tion, images were obtained using a T1-weighted, sagittal 
oriented 3D-magnetization prepared rapid gradient echo 
(MPRAGE) sequence (TR/TE/TI 2100/3.97/1100 ms, 
matrix size 256 × 256, FOV 256 × 256 mm3, flip angle 
12°, slice thickness 1.5 mm, slab 192 mm, bandwidth 
190 Hz/pixel). Axial proton density and T2-weighted 
images were acquired to screen for structural abnormalities 
using 2D double-echo T2-weighted turbo spin echo (TSE) 
sequence (TR 7110 ms, TE 28/84 ms, FOV 240 × 210 mm, 
slice thickness 3 mm, flip 150°, bandwidth 179 Hz/
pixel). A FLAIR sequence (TR/TE/TI 8000/90/2500 ms, 
slice thickness 5 mm, FOV 240 × 168 mm3, voxel size 
0.8 × 0.6 × 5.0 mm, bandwidth 200 Hz/pixel, turbo fac-
tor 13) was used to detect juxtacortical–cortical lesions. All 
anatomic MRI images were read by the University of Utah 
faculty radiologists.
31P-MRS data were acquired using a 3D-MRS sequence 
with elliptically weighted phase encoding, to minimize 
acquisition time, i.e., participant burden. The acquisition 
parameters were: data matrix size 8 × 8 × 8, TR 2000 ms, 
flip angle 90° for hard RF pulse, Rx bandwidth 2.5 kHz, 
complex points 1024, readout duration 409 ms, pre-acqui-
sition delay 2.3 ms, FOV 200 × 200 mm2 and 16 number 
of excitations. Within the Siemens operator interface, the 
RF pulse-transmitted voltage was varied until the maximal 
phosphorus signal intensity within the volume of interest 
(VOI) was achieved. That voltage was deemed to be gener-
ating a 90° flip angle. However due to field inhomogeneity, 
the true RF flip angle may vary across different brain tis-
sues. Therefore to minimize the effects of RF field inhomo-
geneity, 31P-MRS results are expressed as the ratio of the 
individual metabolite concentrations to the total phosphate 
signal acquired from the VOI. Post-processing of 31P-MRS 
data was performed with the jMRUI software application 
(jMRUI v. 4.0, European Community) with the AMARES 
algorithm (Advanced Method for Accurate, Robust and 
Efficient Spectral fitting of MRS data with use of prior 
knowledge). Before fitting the free-induction-decay (FID) 
data, a Hamming filter was applied to reduce signal con-
tamination from neighboring voxels, with apodization of 
10 Hz line broadening. Fourier transformation, frequency 
shifts correction and zero-order/first order phase correction 
as well as baseline correction were applied. The structural 
image-processing tool FSL (FMRIB Software Library, 
Release 4.1, The University of Oxford) was used to esti-
mate the gray matter (GM), white matter (WM) and cer-
ebrospinal fluid (CSF) content of each voxel, to correct 
for the partial volume effects on the metabolite data. The 
MRS grid was positioned over the images in identical fash-
ion for both scans. For each 31P-MRS metabolite, the peak 
area was calculated as a percentage of the total phosphorus 
(TP) signal acquired during the participant’s scan. Figure 1 
shows the region of interest in the frontal lobe slice and a 
representative 31P-MRS spectrum.
Statistical analysis
Group differences in demographic and baseline/pre-treat-
ment variables among the four treatment groups were 
Fig. 1  Frontal lobe region 
of interest for phosphorus-31 
magnetic resonance spectros-
copy scans and a representative 
31P-MRS spectrum. NTP alpha, 
gamma and beta-nucleoside 
triphosphate, PCr phosphocre-
atine, PDE phosphodiesters, 
Pi inorganic phosphate, PME 
phosphomonoesters
1945Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic…
1 3
assessed using the analysis of variance (ANOVA) proce-
dure. The linear mixed model (LMM) procedure was uti-
lized for analysis of the primary outcome measure, frontal 
lobe 31P-MRS PCr, and the secondary outcome measure, 
CDRS-R depression scores (Bland and Altman 1994; Roy 
2006; Cnaan et al. 1997). Because the neuroimaging and 
clinical measures were correlated, repeated measures data, 
a robust estimate of the variance, was obtained by imple-
menting the vce(robust) option (Huber 1967; White 1980) 
in the statistical software Stata® for Linux, release 13 
(StataCorp LP, College Station, TX, USA).
Results
As shown in Table 1 and displayed in the flow diagram in 
Fig. 2, we enrolled a total of n = 34 participants. N = 45 
participants were formally assessed using the K-SADS-PL 
or SCID-CT, of which n = 11 did not meet the diagnos-
tic inclusion criteria. One participant met the criteria, but 
relocated 300 miles from Salt Lake City and, therefore, 
withdrew from further participation prior to her baseline/
pre-treatment scan. Complete data including two 31P-MRS 
scans were available for n = 28 participants. Because the 
Table 1  Participant baseline 
characteristics (N = 34)
CDRS-R Children’s Depression Rating Scale-Revised, CGI-S Clinical Global Impressions-Severity, 





 White 33 97.1 0.39
 African-American 1 2.9
Ethnicity
 Not Hispanic or Latino 32 94.1 0.60
 Hispanic or Latino 2 5.9
Handedness
 Right 30 88.2 0.60
 Left 1 2.9
 Missing 3 8.8
Mean SD
Age (years) 17.1 2.09 0.73
Clinical variables
 Comorbid conditions 1.33 0.85 .046
Clinical Rating Scale Scores
 CDRS-R 57.52 6.29 0.48
 MADRS 26.85 5.68 0.14
 CGI-S 4.42 0.56 0.40
N %
SSRI treatment 0.29
 Fluoxetine 9 27.3
 Citalopram 6 18.2
 Escitalopram 4 12.1
 Sertraline 14 42.4
Concomitant medications 0.48
 Mixed amphetamine salts 1 2.9
 Mirtazapine 1 2.9
 Oral contraceptive 2 5.9
 Bupropion 2 5.9
 Vitamin D 1 2.9
Dropout 5 15.0 0.52
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primary outcome measure of target engagement was frontal 
lobe PCr, statistical analyses were performed on the data 
collected from these ‘protocol completers’. The sample 
included one African-American participant and two partici-
pants who self-identified as Hispanic or Latino.
Table 2 includes the baseline and week 8 outcomes, for 
the protocol completers who were randomized to each of 
four treatment conditions. The results of the ANOVA pro-
cedure indicated that there was no significant difference 
between groups at baseline, in terms of age (p = 0.38), 
pre-treatment frontal lobe PCr (p = 0.75) or CDRS-R raw 
score at study entry (p = 0.51).
In terms of adverse events, gastrointestinal side effects 
were most commonly reported by participants in the pla-
cebo arm (n = 4 of 6; 67 %). Participants experienced 
mild weight gain in all treatment conditions including 
placebo, as measured either in pounds (range 2.33–5.28 
pounds; p = 0.75) or in percent gained (range 1.7–3.9 %; 
p = 0.64). Regarding safety, questions have been raised 
in the literature regarding CM’s potential to impair renal 
function. Accordingly, participants’ serum creatinine levels 
were measured prior to administration of study drug and 
repeated following 8 weeks of randomized treatment. We 
found no significant group difference in participants’ mean 
serum creatinine, either at baseline (range 0.65–0.85 mg/
dL; p = 0.16) or at week 8 (range 0.74–0.88 mg/dL). In 
terms of the tolerability and acceptability of adjunctive CM, 
no subject withdrew from the study due to CM-associated 
adverse events. Participants lost to follow-up included two 
who were unable to tolerate the baseline 31P-MRS scan and 
elected not to repeat it and the participant who relocated. 
No participant attempted suicide or was psychiatrically 
hospitalized, and there were no serious adverse events, as 
defined by the FDA. There were no unresolved treatment-
emergent adverse events, abnormalities on laboratory test-
ing or 12-lead ECGs.
The results of 31P-MRS showed a tendency for fron-
tal lobe PCr to increase by 4.6, 4.1 and 9.1 % in the CM 
2, 4 and 10 g groups, respectively (Fig. 3; p = 0.69). By 
contrast in the placebo group, frontal lobe PCr displayed 
a tendency to decrease by 0.7 %; frontal lobe PCr changes 
across all four treatment groups did not achieve statistical 
significance (Table 2; p = 0.69). We also found that only 
the 10 g CM group demonstrated an increase in frontal lobe 
β-NTP: from baseline to week 8, the observed difference 
in β-NTP was −6.3 % in the placebo group, 0 % in the 2 g 
CM group, −9.1 % in the 4 g CM group and +3 % in the 
10 g CM group (p = 0.47).
However as shown in Fig. 4, when the three active CM 
treatment groups were combined (n = 25) and compared 
Fig. 2  Participant flow dia-
gram: screening, randomization 
and disposition of adolescent 
females with treatment-resistant 
major depressive disorder. FU 
follow-up, SSRI selective sero-
tonin reuptake inhibitor, WC 
withdrew consent
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with the placebo group (n = 8) utilizing an LMM analy-
sis of frontal lobe PCr versus CDRS-R scores, there was 
a significant negative correlation in the CM-treated group, 
i.e., higher frontal lobe PCr correlates with lower depres-
sion scale scores (p = 0.03); this relationship was not 
present in the placebo group. Furthermore, when the four 
treatment groups are combined and all frontal lobe PCr 
measurements are regressed versus all CDRS-R depres-
sion scores recorded at study scan visits, the negative cor-
relation between frontal lobe PCr and CDRS-R scores 
becomes marginally more significant (p = 0.02), as shown 
in the left panel of Fig. 5. The right panel of Fig. 5 dis-
plays the individual scatter plots of the placebo, CM 2, 4 
and 10 g groups. Visual inspection of the regression lines 
suggests that the 4 and 10 g treatment groups were respon-
sible for the majority of the variance in the relationship 
between frontal lobe PCr and CDRS-R score. 31P-MRS 
can also be used to measure local concentrations of phos-
phomonoesters (PME) and phosphodiesters (PDE). PME 
consist of phospholipid membrane precursors, while PDE 
are phospholipid breakdown products. Although we found 
no significant between-group differences in post-treatment 
PME, visual inspection of the raw data shows that PME/
TP decreased by 9 % in the placebo group, while PME/
TP was marginally increased in the three active CM treat-
ment groups. While no conclusion can be drawn from this 
observation, it is perhaps notable that vesicular uptake of 
glutamate, a neurotransmitter implicated in mood disor-
ders, may be regulated by PME and PCr (Xu et al. 1997). 
The results of the analysis of the mean percent tissue con-
tent of the VOI among the four treatment groups were as 
follows: GM pre-treatment (p = 0.32), GM post-treatment 
Table 2  Protocol completer 
outcome measures: means and 
standard deviations
CDRS-R Children’s Depression Rating Scale, Revised, TP total phosphorus signal, PCr phosphocreatine, 
β-NTP beta-nucleoside triphosphate, PME phosphomonoester, PDE phosphodiester
Variable Placebo Creatine 2 g Creatine 4 g Creatine 10 g p value
anova
Number of participants N = 6 N = 7 N = 8 N = 7 –
Mean age (years) 16.8 (1.06) 17.6 (1.86) 16.4 (2.63) 17.0 (2.61) 0.38
PCr/TP (N = 28)
 Frontal lobe, baseline 0.149 (0.005) 0.151 (0.006) 0.145 (0.005) 0.143 (0.005) 0.75
 Frontal lobe, final 0.148 (0.004) 0.158 (0.004) 0.151 (0.003) 0.156 (0.003) 0.32
 Change (%) −0.7 +4.6 +4.1 +9.1 0.69
β-NTP/TP (N = 28)
 Frontal lobe, baseline 0.111 (0.015) 0.106 (0.013) 0.109 (0.011) 0.100 (0.021) 0.55
 Frontal lobe, final 0.104 (0.008) 0.106 (0.015) 0.099 (0.001) 0.103 (0.012) 0.86
 Change (%) −6.3 0 −9.1 +3 0.47
PME/TP (N = 28)
 Frontal lobe, baseline 0.145 (0.012) 0.134 (0.020) 0.138 (0.011) 0.140 (0.009) 0.53
 Frontal lobe, final 0.132 (0.011) 0.138 (0.013) 0.145 (0.014) 0.143 (0.008) 0.28
 Change (%) −9.0 3.0 5.1 2.1 0.72
PDE/TP (N = 28)
 Frontal lobe, baseline 0.163 (0.022) 0.167 (0.017) 0.169 (0.007) 0.167 (0.019) 0.93
 Frontal lobe, final 0.169 (0.007) 0.159 (0.018) 0.171 (0.020) 0.163 (0.011) 0.54
 Change (%) 3.7 −4.8 1.2 2.4 0.60
CDRS-R mean raw score
 Baseline 58.2 (3.96) 62.5 (9.35) 58.0 (8.53) 56.9 (5.05) 0.51
 Final 43.0 (12.58) 34.8 (8.20) 41.8 (14.78) 36.1 (13.96) 0.59
 Change (%) −26 −44 −29 −37 –
Participants reporting
Gastrointestinal adverse events
n = 4/6 n = 2/7 n = 5/8 n = 4/7 –
Weight gain
 Pounds 2.83 (3.65) 2.90 (2.39) 2.33 (8.54) 5.28 (3.80) 0.75
 Percent +1.8 +2.2 +1.7 +3.9 0.64
Serum creatinine
 Baseline (mg/dL) 0.78 (0.056) 0.85 (0.066) 0.65 (0.056) 0.77 (0.056) 0.16
 Final (mg/dL) 0.79 (0.051) 0.84 (0.062) 0.74 (0.057) 0.88 (0.053) 0.32
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(p = 0.73), WM pre-treatment (p = 0.15), WM post-treat-
ment (p = 0.79), CSF pre-treatment (p = 0.82), CSF post-
treatment (p = 0.92). 
Finally, Fig. 6 displays the percent change in CDRS-
R clinical depression scores by treatment group, over the 
8 weeks of randomized treatment. We did not find a sta-
tistically significant between-group difference in CDRS-
R scores at week 8 (p = 0.59), nor does the change in 
depression score appear to be dose-dependent. This may 
be related to the study sample size and the fact that par-
ticipants randomized to the 2 g group had the highest 
mean CDRS-R score at baseline. Among the four groups, 
participants in the 2 g daily (mean CDRS-R = 34.8) and 
10 g daily (mean CDRS-R = 36.1) groups no longer met 
the study’s depression severity inclusion criterion (CDRS-
R > 40) at the end of treatment.
Discussion
The authors report the results of what is, to the best of our 
knowledge, the first 31P-MRS experimental medicine dose-
ranging study of adjunctive CM for female adolescents 
with SSRI-resistant MDD. While our results diverge with 
those of a recent dose-ranging study of CM augmentation 
in adults with TRD (Nemets and Levine 2013), the out-
come of interest in the present report was PCr measured 
with translational 31P-MRS neuroimaging. As found in 
our previous open-label study (Kondo et al. 2011b), aug-
mentation of SSRI pharmacotherapy with CM was associ-
ated with increased frontal lobe PCr. Open treatment with 
4 g CM daily was associated with a 6.4 % increase in the 
prior trial. In the present study, adjunctive 2, 4 and 10 g of 
CM daily for a total of 8 weeks was associated with ten-
dencies toward increased frontal lobe PCr of 4.6, 4.1 and 
9.1 %, respectively. By comparison, participants in the 
placebo group demonstrated a tendency toward decreased 
frontal lobe PCr of 0.7 %. In addition, target engagement 
with frontal lobe PCr was correlated with scores on the 
standard measure of depression severity employed in child 
psychiatry clinical trials, the CDRS-R (Figs. 3, 4). In terms 
of outcomes, participants randomized to the 2 g dose of 
CM appeared to show a tendency toward the most robust 
clinical response, as measured by CDRS-R scores (Fig. 6); 
however, this was not statistically significant (p = 0.59). 
This squares with what little is known regarding the 
response to placebo vs. active pharmacotherapy in adoles-
cents with TRD. Zhou et al. (2014) performed a systematic 
review of adolescent TRD treatments and found that the 
only randomized, placebo-controlled trial in this population 
found no difference in the response rate to amitriptyline 
(76.9 %) versus placebo (78.6 %) (Birmaher et al. 1998). 
The largest study of adolescent TRD conducted to date is 
the TORDIA clinical trial, which did not include a placebo 
arm among its four treatment conditions (Brent et al. 2008). 
Meanwhile, the NIMH has adopted the experimental medi-
cine model for clinical research, moving away from tests 
of clinical efficacy to focus on disease mechanisms (Insel 
and Gogtay 2014; Insel 2015). The present dose-ranging 
study found that CM 10 g achieves target engagement with 
PCr, while concomitant increases in adverse events such 
as gastrointestinal symptoms, weight gain or increased 
Fig. 3  Pre- versus post-treatment frontal lobe phosphocreatine (PCr/
TP) in participants randomized to treatment with placebo or creatine 
2, 4 or 10 g daily (N = 28)
Fig. 4  Correlation between Children’s Depression Rating Scale-
Revised (CDRS-R) scores and frontal lobe phosphocreatine (PCr/TP) 
and in participants randomized to placebo (left) versus active treat-
ment (right) with creatine 2, 4 or 10 g (*p = 0.03)
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serum creatinine were not observed. Adding to the ration-
ale for selecting the 10 g dose is the fact that pre-treatment 
PCr is an accurate predictor of treatment response in TRD 
(Iosifescu et al. 2008), and creatine’s neuroprotective 
effect on brain bioenergetics is dose dependent, occurring 
at higher dosages (Atassi et al. 2010). Thus the relevance 
of the target, and its engagement by CM, appeared to be 
confirmed, and development of adjunctive CM as a treat-
ment for TRD in adolescent females will continue. We have 
opened recruitment on the next phase of development, an 
NIMH-sponsored R33 placebo-controlled pilot study of 
CM 10 g for female adolescents with SSRI-resistant MDD, 
the results of which can be used to inform the design and 
implementation of a larger-scale efficacy study.
In addition to PCr, another measure of mitochondrial 
function often reported in 31P-MRS studies of MDD is 
β-NTP, which is considered a proxy measure for the con-
centration of ATP. We did not find a discernible tendency 
in alterations in frontal lobe β-NTP in this study. How-
ever, there are important differences in the study samples, 
participant characteristics and VOI, between previous 
reports and the present study. For example, we previously 
reported that in healthy adult males, administration of CM 
for 14 days was associated with a significant decrease in 
the β-NTP resonance (p = 0.026) obtained from axial 
brain slice through the orbitofrontal and occipital corti-
ces (Lyoo et al. 2003). We also found an 18 % decrease 
in basal ganglia β-NTP (p < 0.03), in unmedicated adults 
with MDD versus healthy volunteers (Moore et al. 1997). 
This was followed by our report that basal ganglia β-NTP 
is 21 % lower in MDD treatment responders versus non-
responders (p = 0.02) to SSRI fluoxetine (Renshaw et al. 
2001). Another group reported decreased β-NTP in the 
frontal lobe (p = 0.001), in a sample of n = 14 adult men 
and women with MDD compared with n = 10 healthy vol-
unteers (Volz et al. 1998). The distinctions between these 
findings and the current report include the adolescent age 
group, an all-female sample and the fact that all of our par-
ticipants were not only medicated, but treatment resistant at 
baseline, i.e., “non-responders.” When added to the fact that 
the earlier studies were performed on 1.5 T scanning sys-
tems, these systematic differences in (1) magnet strength; 
(2) gender; (3) age range; (4) depression severity; (5) medi-
cation status; and (6) VOI, could plausibly account for the 
Fig. 5  Correlation between 
Children’s Depression Rating 
Scale-Revised (CDRS-R) scores 
and frontal lobe phosphocre-
atine (PCr/TP) and in the entire 
sample (p = 0.02). Right panel 
scatter plot of the correlation 
between Children’s Depression 
Rating Scale-Revised (CDRS-
R) scores and frontal lobe PCr/
TP, displayed by treatment 
group: placebo, 2 g creatine, 
4 g creatine and 10 g creatine. 
Left panel negative correlation 
between changes in Children’s 
Depression Rating Scale-
Revised (CDRS-R) scores and 
frontal lobe phosphocreatine/
total phosphorus signal (PCr/
TP) across all phosphorus 
magnetic resonance spec-
troscopy scans, i.e., lower 
depression scores correlate with 
higher PCr/TP concentrations 
(*p = 0.02)
Fig. 6  Percent Change in Children’s Depression Rating Scale-
Revised (CDRS-R) scores from baseline to week 8, displayed by 
treatment group (N = 28)
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difference in findings with respect to β-NTP. Furthermore 
in their seminal 31P-MRS report, Kato et al. (1992) found 
no significant differences in β-NTP concentration among 
the following groups: MDD depressed, MDD euthymic, 
bipolar depressed, bipolar euthymic and healthy controls. 
In contrast, however, PCr was significantly decreased in 
severe versus mild MDD, and there was a non-significant 
tendency toward decreased PCr in bipolar depressed versus 
bipolar euthymic subjects (Kato et al. 1992).
MDD is a chronic, recurrent illness that frequently has 
its origins in adolescence (Burke et al. 1991). Unfortu-
nately, the current antidepressants appear to possess lim-
ited efficacy in juvenile depression (Tsapakis et al. 2008), 
and adolescent MDD (Avenevoli et al. 2015) and TRD 
(Zhou et al. 2014) remain substantial public health con-
cerns. The scope of the problem is highlighted by the fact 
that 350 million individuals suffer from depression world-
wide (World Health Organization 2015). Depression costs 
are estimated at $200 billion annually in the USA (Mrazek 
et al. 2014), surpassing the total spent on cancer or diabetes 
mellitus (Ionescu et al. 2015). Because the burden of MDD 
falls disproportionately on girls and women, successful 
development of interventions for female adolescents in this 
critical period of development could have a broad impact 
on public health.
The mitochondrial dysfunction associated with depres-
sion (Gardner and Boles 2011; Klinedinst and Regen-
old 2015) presents a tractable target for developing novel 
therapeutics and may also offer opportunities to improve 
the efficiency of drug development (Manji et al. 2012). In 
the context of the NIMH Experimental Medicine Initia-
tive (Insel 2015), 31P-MRS is a translational tool capable 
of measuring ‘target engagement’ by quantifying the high-
energy phosphorus-bearing neurometabolites involved in 
brain bioenergetics (Iosifescu and Renshaw 2003; Kato 
et al. 1992). One of these, PCr, has been shown to predict 
treatment response in patients who have not responded to 
antidepressant pharmacotherapy (Iosifescu et al. 2008) 
and thus present a rational treatment target in TRD. This 
study joins prior reports from our group (Lyoo et al. 2003; 
Hellem et al. 2015; Kondo et al. 2011b) and others (Pan 
and Takahashi 2007; Bianchi et al. 2007) in providing 
in vivo evidence that oral CM administration achieves tar-
get engagement with brain bioenergetics and the creatine 
kinase system.
Numerous directions for further study of CM suggest 
themselves. For example, all protocol completers in the 
present study were offered a 6-month open-label exten-
sion of CM 4 g daily, the dose administered in our open-
label study. The rationale for this is twofold. Foremost is 
the obligation the investigators feel to offer participants 
randomized to placebo an opportunity to benefit from CM 
augmentation. Additionally, it is important to assess the 
durability of treatment effects and to collect long-term 
safety and tolerability data. The results of the 6-month 
extension study will be reported separately. Mechanisti-
cally, there is still much to be learned regarding CM’s 
downstream effects in the brains of depressed individuals. 
A series of elegant experiments from the Rodrigues labora-
tory point toward an overlap in the neurobiological path-
ways involved in the antidepressant-like effect of CM in 
animal models and those of ketamine (Cunha et al. 2014, 
2015a, b, c). It is perhaps notable that ketamine is con-
sidered a ‘rapid’ antidepressant, and in our study of adult 
females with MDD, CM appeared to accelerate the anti-
depressant effects of the SSRI escitalopram (Lyoo et al. 
2012). Based upon the gender dimorphism of creatine’s 
effects in our rodent studies (Allen et al. 2010, 2012), there 
is the intriguing possibility of studying CM’s antidepres-
sant effect as monotherapy for untreated female adolescents 
with MDD. Given that antidepressants increase the risk of 
suicidal behavior in depressed youth (Hammad et al. 2006), 
this strategy may be worth exploring. Finally, in considera-
tion of the converging evidence for sex-based differences in 
brain mitochondrial functioning (Demarest and McCarthy 
2015), there may also be opportunities to explore gender-
specific pharmacotherapies in depression. We have taken an 
initial step in that direction, with a study of CM supplemen-
tation to target depressive symptomatology in females with 
substance use disorders (Hellem et al. 2015). The gender 
dimorphism in rodent creatine kinase activity in brain has 
led investigators to conclude that females are more depend-
ent on the system, between sexual maturity and senescence 
(Ramirez and Jimenez 2002). Recent data indicate that gen-
der, sex hormones and metabolic status mediate the behav-
ioral and neurochemical effects of CM supplementation. 
Specifically, combined CM and sex hormone treatment 
normalizes neuroplasticity-related gene expression in gona-
dectomized rats of both sexes and has an antidepressant-
like effect in females (Allen et al. 2015). Given these find-
ings and the evidence for sexual dimorphism in how brain 
mitochondria respond to both stress-depression paradigms 
and to subsequent treatment with SSRI medications (Adzic 
et al. 2013), further investigation of antidepressant strate-
gies targeting brain bioenergetics in females with MDD is 
warranted.
This study’s findings should be interpreted in light of 
several limitations. Chief among these is its small sample 
size, which limited our power to detect differences in the 
primary and secondary outcome measures between our 
four treatment groups. Two studies of adolescent depres-
sion implementing interventions other than CM, the TADS 
(March et al. 2004) and TORDIA (Brent et al. 2008) clini-
cal trials, randomized n = 439 and n = 334 participants, 
respectively, to four different treatment groups. Further-
more, dose-ranging studies that employ conventional 
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clinical outcomes must enroll > 100 participants per dosing 
regimen tested (Erondu et al. 2006). Sample sizes of that 
magnitude are not feasible for translational neuroimaging 
studies and point toward the rationale for transitioning to 
‘target engagement’ as the primary outcome measure for 
human subject research in the NIMH Experimental Medi-
cine Initiative (Potter 2015). Another limitation is the low 
rate of creatine transporter (SLC6A8) expression in human 
brain endothelium (Lowe et al. 2015), which supports the 
suggestion that there is modest permeability for creatine 
at the blood–brain barrier (Braissant et al. 2001) and that 
de novo synthesis in glia may serve as the principal source 
of creatine in brain (Braissant et al. 2007; Tachikawa et al. 
2004). Following intraperitoneal injection of creatine to 
rats, no significant increase in either creatine or PCr can 
be measured (Perasso et al. 2003). A recent report used 
established methods to estimate dietary creatine intake 
(Harris et al. 1997) and concluded that that diet does not 
influence brain creatine content and that the human brain 
is dependent on its own creatine biosynthesis (Yazigi Solis 
et al. 2014). While our own clinical trials (Lyoo et al. 2003; 
Hellem et al. 2015; Kondo et al. 2011b) and those of other 
investigators (Dechent et al. 1999; Atassi et al. 2010; Turner 
et al. 2015; Pan and Takahashi 2007) support the idea that 
CM administration alters creatine and/or PCr in brain, it is 
a limitation that all of these studies used a single method—
magnetic resonance spectroscopy—to measure subjects’ 
brain chemistry. A frequent limitation of neuroimaging 
studies in psychiatry is the potential for confounding due 
to psychotropic medications, and the present report is no 
exception. Previous reports have documented the potential 
for antidepressants to alter neuroimaging results in females 
with MDD (Kaymak et al. 2009) and in adolescents (Singh 
and Chang 2012). Thus, it must be acknowledged that 
SSRI administration may have added noise to our 31P-MRS 
acquisitions, for which the signal-to-noise ratio is a critical 
source of variance. A final limitation that restricts the gen-
eralizability of our findings is that we studied only females. 
Future studies of CM in male adolescents with TRD may 
be warranted, but for ethical reasons we will need to await 
completion of at least one trial demonstrating CM’s safety 
in adult males with depression.
In summary, we present the results of a double-blind, 
randomized, placebo-controlled dose-ranging clinical trial 
of adjunctive CM for female adolescents with SSRI-resist-
ant MDD. Participants receiving 10 g appeared to show 
a greater degree of alteration in brain energy metabolism 
measured with repeated 31P-MRS neuroimaging, without 
concomitant differences in adverse events, tolerability or 
treatment acceptability. Furthermore, frontal lobe PCr, the 
putative target of CM administration, demonstrated a corre-
lation with clinical measures of depression across our study 
sample. Our results join converging lines of evidence from 
multiple scientific disciplines suggesting that CM may pro-
vide benefit in a range of brain-based disorders (Rae and 
Broer 2015; Allen 2012). We have now opened recruit-
ment on a two-arm, placebo-controlled trial of CM 10 g for 
female adolescents with TRD. The results of that study will 
inform Go/No Go decision making regarding further devel-
opment of CM and provide insight into the utility of adopt-
ing the experimental medicine framework for the discovery 
and validation of novel treatments in psychiatry.
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